Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Physical activity and quality of life in patients with pulmonary hypertension

Thomas M. Cascino, Vallerie V. McLaughlin, Caroline R. Richardson, Nilofar Behbahani-Nejad, Victor M. Moles, Scott H. Visovatti, Elizabeth A. Jackson
European Respiratory Journal 2019 53: 1900028; DOI: 10.1183/13993003.00028-2019
Thomas M. Cascino
1Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tcascino@med.umich.edu
Vallerie V. McLaughlin
1Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline R. Richardson
2Dept of Family Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nilofar Behbahani-Nejad
3Oakland University William Beaumont School of Medicine, Auburn Hills, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor M. Moles
1Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott H. Visovatti
1Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A. Jackson
4Division of Cardiovascular Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In a longitudinal study of stable pulmonary hypertension patients, there was a nonlinear association between 6MWD and step counts at higher levels of exercise capacity and average step counts were associated with disease-specific and global HRQoL http://bit.ly/2JiCvRX

To the Editor:

Pulmonary arterial hypertension (PAH) is a progressive, non-curable disease with significant associated comorbidity, including reduced exercise capacity [1] and poor health-related quality of life (HRQoL) [2]. Exercise capacity is frequently measured using the 6-min walk test (6MWT) [3]. The 6MWT is easy to perform and correlates with disease severity and HRQoL [4]. However, the 6MWT has limitations such as the need for a clinic visit to perform it [4] and ceiling effects which reduce the sensitivity to changes among patients [5].

Commercially available activity trackers have the potential to monitor ambulatory function continuously beyond one-time measures of exercise capacity. For the PAH population, data on ambulatory activity may provide a more sensitive means to assess changes in clinical status [4] and be informative in the assessment of new therapies. However, an understanding of the long-term correlation between physical activity and both 6-min walking distance (6MWD) and patient-centred outcomes, such as HRQoL, is needed as prior studies were limited to short-term follow-up [6–9].

The primary aims of this prospective cohort study were to assess the correlation between 6MWD and physical activity (step counts) and to examine associations between physical activity and HRQoL among patients with PAH and chronic thromboembolic pulmonary hypertension (CTEPH) over an extended period.

We enrolled patients ≥18 years-old from the University of Michigan Medical Center between June and November 2016 at the time of a PAH clinic visit and followed them until their next scheduled appointment. Participants were included if they had a diagnosis of PAH or CTEPH according to World Health Organization (WHO) criteria [10] and WHO functional class I to III symptoms [3] on stable PAH medications for ≥3 months without comorbid conditions that limited activity. The study was approved by the Institutional Review Board and informed consent was obtained (HUM00110649).

At each visit, a 6MWT was performed and physical activity quantified using average daily step counts for 2 weeks acquired with the Fitbit Zip accelerometer (Fitbit, San Francisco, CA, USA). Days with <200 steps were excluded and weeks with ≥4 excluded days were considered non-valid. Participants were instructed to wear the Fitbit Zip during waking hours and to continue their usual level of activity. HRQoL was measured using the emPHasis-10 questionnaire, a PAH-specific instrument used to determine the impact of PAH symptoms on patients' lives [11], and several non-disease specific Patient-Reported Outcomes Measurement Information System (PROMIS) short-form domain measures (physical function-v1.2, fatigue-v1.0, illness impact-v1.0, satisfaction with roles-v1.0 and ability to participate in social roles-v2.0) [12].

The primary outcomes of the study were: 1) correlation of 6MWT and physical activity, 2) association between physical activity and HRQoL, and 3) association between physical activity change and HRQoL change between baseline and follow-up. Visual inspection of scatterplots suggested a curvilinear relationship between step counts and 6MWD. The inclusion of step count as a second-order term (quadratic) improved the model fit. A p-value of <0.05 was used to determine significance. Analyses were conducted using STATA 14 (StataCorp LP, College Station, TX, USA).

Of the 87 consecutive patients screened, 36 either didn't meet inclusion criteria or met exclusion criteria, 11 were eligible but did not participate, and one enrolled but elected not to participate, leaving 39 participants in the study (mean±sd age 61±12 years, 85% (n=33) female, 90% PAH (n=35) and 10% CTEPH (n=4)). A total of 34 participants (87%) had valid mean step counts for the initial visit, 69% (n=27) for the follow-up visit, and 64% (n=25) for both and were included in the change between visits analysis. Participants were followed for a median (interquartile range) of 6.1 (4.6–6.4) months between visits.

The mean±sd steps and 6MWD were 4391±2442 steps and 460±107 m. Average daily step count was significantly associated with 6MWD (R=0.71, R2=0.51, p<0.001) (figure 1a). Average daily step counts and HRQoL measures remained stable between visits. Higher average daily step counts were positively associated with lower pulmonary hypertension symptoms burden (emPHasis-10 score) and PROMIS domains, including higher self-reported function, lower fatigue, higher satisfaction with social roles and decreased psychosocial illness impact (figure 1b). The adjusted analyses examining the association between change in step counts and change in HRQoL measures are also reported in figure 1b and reflect the clinical stability in all measures between visits.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

a) Scatter plot with regression line showing the relationship between 6-min walking distance (6MWD) and average daily step counts. Average daily step count was significantly associated with 6MWD (R=0.63, R2=0.39, p<0.001). Model fit improved when step counts were included as a second order variable (R=0.71, R2=0.51, p<0.001) (shown in figure). b) Results of the multivariable linear regressions adjusting for age and sex. Health-related quality of life (HRQoL) and change in HRQoL were the dependent variables with average daily step counts and change in average daily step counts the primary independent variables. Regression coefficient with standard errors in parentheses, p-value and R2 displayed for each model. The emPHasis-10 score ranges from 0–50 with higher scores representing worse symptom burden and quality of life [12]. Patient-Reported Outcomes Measurement Information System (PROMIS) results are transformed using a T-score metric with a mean of 50 and a standard deviation of 10 for the general US population. A higher score indicates more of the domain being evaluated [13].

Our findings support the stability and reliability of continuous long-term monitoring of physical activity in PAH and CTEPH patients. Over a median follow-up of about 6 months in clinically stable participants, physical activity measured by average daily step counts did not change and was strongly associated with 6MWD. The current use of 6MWD to monitor exercise capacity is well-established. Thus, 6MWD is frequently used as an efficacy outcome in clinical trials [13]. However, given the limitations, there has been increasing interest in using continuous device monitoring to assess ambulatory function [4]. The confirmation of the stability and reliability of physical activity using measures over an extended period builds on prior work of shorter duration and is a necessary first step in understanding if physical activity monitoring adequately addresses these limitations [6–9].

In addition, there was a high correlation between physical activity and 6MWD, which has been previously described [6–8]. However, we observed this relationship to be nonlinear suggesting that at higher ambulatory activity (daily step counts), the 6MWD lost discriminatory value. This may represent the previously reported ceiling effect where the 6MWT was unable to differentiate response to therapies in participants with higher exercise capacity [5]. With the use of early combination therapies, participants enrolling in clinical trials are changing and tend to have improved exercise tolerance limiting the ability to use 6MWD in these patients [14]. Our findings suggest that ambulatory step count monitoring has the potential to be more sensitive to changes in functional capacity among active individuals.

Ambulatory step count monitoring in our study was associated with HRQoL, including the emPHasis-10 survey and several general health domains. These findings are particularly important given the evolving emphasis at the World Symposium on Pulmonary Hypertension on translating clinical trial results into meaningful outcomes for participants rather than less patient-centred outcomes such as 6MWD [15]. As a result, home activity monitoring has the potential to offer a more complete understanding of ambulatory activity and should be considered as an exploratory patient-centred outcome in clinical trials.

Our study has limitations. Overall, participants found using the Fitbit Zip to be acceptable, wearing the device for 77% of eligible days. Despite this, 36% of participants (14 out of 39) did not provide step count data at both visits. Involving patients in the research design may better elucidate the optimal strategy to improve compliance. Although our median follow-up was 6 months, the duration was too short in this clinically stable group to detect changes in physical activity and HRQoL. A larger, longer study or a study aimed at increasing physical activity is necessary to determine if physical activity is sensitive to change or if improving physical activity improves clinically important outcomes.

Our results suggest step counts provide a clinically useful method for measuring ambulatory function among patients with PAH and CTEPH, which correlated with 6MWD and HRQoL. It is recommended that investigators using devices which measure step counts examine their data for nonlinear correlations with other measures. Finally, given the relationship of daily physical activity and HRQoL, future studies which promote regular physical activity with a goal of improving HRQoL are warranted.

Footnotes

  • Conflict of interest: T.M. Cascino reports grants from National Institutes of Health and from University of Michigan Frankel Cardiovascular Center, during the conduct of the study.

  • Conflict of interest: V.V. McLaughlin reports personal fees from Actelion Pharmaceuticals US, Inc., Bayer, Gilead Sciences, Inc., Medtronic, Merck, St. Jude Medical and United Therapeutics Corporation, and grants from Actelion Pharmaceuticals US, Inc., Arena, Bayer and Sonovie (University of Michigan received research funding), all outside the submitted work.

  • Conflict of interest: C.R. Richardson has nothing to disclose.

  • Conflict of interest: N. Behbahani-Nejad has nothing to disclose.

  • Conflict of interest: V.M. Moles has nothing to disclose.

  • Conflict of interest: S.H. Visovatti has nothing to disclose.

  • Conflict of interest: E.A. Jackson has nothing to disclose.

  • Support statement: This study was funded by a Michigan Medicine Frankel Cardiovascular Center Micro Grant and National Institutes of Health T32 postdoctoral research training grant (T32-HL007853). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received December 18, 2018.
  • Accepted March 6, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Delcroix M,
    2. Howard L
    . Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015; 24: 621–629.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Mathai SC,
    2. Suber T,
    3. Khair RM, et al.
    Health-related quality of life and survival in pulmonary arterial hypertension. Ann Am Thorac Soc 2016; 13: 31–39.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Galie N,
    2. Humbert M,
    3. Vachiery JL, et al.
    2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
    OpenUrlCrossRefPubMed
  4. ↵
    1. McLaughlin V,
    2. Bacchetta M,
    3. Badesch D, et al.
    Update on pulmonary arterial hypertension research: proceedings from a meeting of experts. Curr Med Res Opin 2018; 34: 263–273.
    OpenUrl
  5. ↵
    1. Frost AE,
    2. Langleben D,
    3. Oudiz R, et al.
    The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005; 43: 36–39.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Mainguy V,
    2. Provencher S,
    3. Maltais F, et al.
    Assessment of daily life physical activities in pulmonary arterial hypertension. PLoS One 2011; 6: e27993.
    OpenUrlCrossRefPubMed
    1. Pugh ME,
    2. Buchowski MS,
    3. Robbins IM, et al.
    Physical activity limitation as measured by accelerometry in pulmonary arterial hypertension. Chest 2012; 142: 1391–1398.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Matura LA,
    2. Shou H,
    3. Fritz JS, et al.
    Physical activity and symptoms in pulmonary arterial hypertension. Chest 2016; 150: 46–56.
    OpenUrl
  8. ↵
    1. Okumus G,
    2. Aslan GK,
    3. Arseven O, et al.
    The role of an activity monitor in the objective evaluation of patients with pulmonary hypertension. Clin Respir J 2018; 12: 119–125.
    OpenUrl
  9. ↵
    1. McLaughlin VV,
    2. Archer SL,
    3. Badesch DB, et al.
    ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573–1619.
    OpenUrlFREE Full Text
  10. ↵
    1. Yorke J,
    2. Corris P,
    3. Gaine S, et al.
    emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J 2014; 43: 1106–1113.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Cella D,
    2. Yount S,
    3. Rothrock N, et al.
    The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; 45: Suppl. 1, S3–S11.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Demir R,
    2. Kucukoglu MS
    . Six-minute walk test in pulmonary arterial hypertension. Anatol J Cardiol 2015; 15: 249–254.
    OpenUrl
  13. ↵
    1. McLaughlin VV
    . Has the 6-min walk distance run its course? Chest 2012; 142: 1363–1365.
    OpenUrlCrossRefPubMed
  14. ↵
    1. McGoon MD,
    2. Ferrari P,
    3. Armstrong I, et al.
    The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019; 53: 1801919.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 53 Issue 6 Table of Contents
European Respiratory Journal: 53 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Physical activity and quality of life in patients with pulmonary hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Physical activity and quality of life in patients with pulmonary hypertension
Thomas M. Cascino, Vallerie V. McLaughlin, Caroline R. Richardson, Nilofar Behbahani-Nejad, Victor M. Moles, Scott H. Visovatti, Elizabeth A. Jackson
European Respiratory Journal Jun 2019, 53 (6) 1900028; DOI: 10.1183/13993003.00028-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Physical activity and quality of life in patients with pulmonary hypertension
Thomas M. Cascino, Vallerie V. McLaughlin, Caroline R. Richardson, Nilofar Behbahani-Nejad, Victor M. Moles, Scott H. Visovatti, Elizabeth A. Jackson
European Respiratory Journal Jun 2019, 53 (6) 1900028; DOI: 10.1183/13993003.00028-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
  • Fixed breathing protocols in multiple-breath washout testing in children
Show more Agora

Research letters

  • Leukocyte telomere length and mycophenolate therapy in CHP
  • Connexins and the pulmonary vascular response to hypoxia
  • Fixed breathing protocols in multiple-breath washout testing in children
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society